Science

Mar 30, 2025, 13:32

Myeloma Paper of the Day, March 30th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Flatiron health record analysis comparing carfilzomib dosing in relapsed/refractory myeloma finds no support for improved outcomes with 2x weekly dosing; K56-1x may best balance efficacy, safety and avoidance of time toxicity.”

“Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis”

Authors: Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Adam Sperling, Larry Anderson Jr, Vincent Rajkumar, Gurbakhash Kaur et al.

More posts featuring Robert Orlowski.

Adam Sperling Adeel M. Khan cancer Gurbakhash Kaur Larry Anderson Jr Mengru Wang multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Rahul Banerjee Relapsed or Refractory Multiple Myeloma Robert Orlowski RRMM Sharlene Dong Vincent Rajkumar Xiaoliang Wang

20 Posts Not to Miss from ASCO 2025

Jessie J Diagnosed with Early-Stage Breast Cancer: What Is the Prognosis?

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL

15 Posts Not to Miss from the 4th Day of ASCO 2025

15 Posts Not to Miss from the 3rd Day of ASCO 2025